Plasmapheresis in immunologically mediated polyneuropathies

Therapeutic Apheresis

Volumn 7, Issue 2, 2003, Pages 189-196

  Kiprov, Dobri D ^a,b   Hofmann, Jan C ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Apheresis; Immunologic; Peripheral Neuropathy; Plasma Exchange; Plasmapheresis; Polyneuropathy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTICOAGULATION; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PLASMAPHERESIS; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; TREATMENT INDICATION; TREATMENT PLANNING; WALDENSTROEM MACROGLOBULINEMIA;

HIV INFECTIONS; HUMANS; IMMUNE SYSTEM DISEASES; PLASMAPHERESIS; POLYNEUROPATHIES;

EID: 0038646274     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00028.x     Document Type: Article

References (73)

1. Pfaeffl W, Qwasmeh A, Kiprov D, Complement activation in apheresis procedures. In: Smeby L, Jorstad S, Wideroe T, eds. Immune and Metabolic Aspects of Therapeutic Blood Purification Systems. Basel: Karger, 1986;323-8.
2. Kiprov D, Dau P, Morand P. The effect of plasmapheresis and drug immunosuppression on T-cell subsets as defined by monoclonal antibodies. J Clin Apher 1983;1:57-63.
3. Kiprov D, Miller R. Paraproteinemia associated with demyelinating polyneuropathy or myositis: Treatment with plasmapheresis and immunosuppressive drugs. Artif Organs 1985;9:47-52.
4. Kiprov D, Miller R. Polymyositis associated with monoclonal gammopathy. Lancet 1984;2:1183-6.
5. McLeod BC. Introduction to the third special issue. Clinical applications of therapeutic apheresis. J Clin Apher 2000;15:1-5.
6. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 2000;15:74-128.
7. Siami GA, Siami FS. Plasmapheresis and paraproteinemia: monoclonal gammopathy. Ther Apher 1999;3:8-19.
8. Kiprov D, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J. Adverse reactions associated with mobile therapeutic apheresis. Analysis of 17,940 procedures. J Clin Apher 2001;16:130-3.
9. McLeod BC, Sassetti RJ, Stefoski D, Davis FA. Partial plasma protein replacement in therapeutic plasma exchange. J Clin Apheresis 1983;1:115-8.
10. McLeod BC, Price TH, Owen H et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999;39:282-8.
11. Sturgill BC, Wofrzniak MJ. Stimulation of proliferation of 19S antibody-forming cells in the spleens of immunized guinea pigs after exchange transfusion. Nature 1970;228:1304-5.
12. Dau PC, Callahan J, Parker R, Golbus J et al. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991;18:270-6.
13. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1131-6.
14. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of opthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65.
15. Baldwin RT, Pierce RR, Frazier OH, Guillain-Barré syndrome after heart transplantation. J Heart Lung Transplant 1992;11:817-19.
16. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002;15:633-8.
17. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 2002;15:333-8.
18. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J Autoimmun 2000;14:1-10.
19. McEneaney D, Hawkins S, Trimble E, Smye M. Porphyric neuropathy - a rare and often neglected differential diagnosis of Guillain-Barre syndrome. J Neurol Sci 1993;114:231-2.
20. Harrison BM, Hansen LA, Pllard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann Neurol 1984;15:163-70.
21. Feasby TE, Hahn AF, Gilbert JJ. Passive transfer studies in Guillain-Barre polyneuropathy. Neurology 1982;32:1159-67.
22. Koski CL, Humphrey R, Shin ML. Anti-peripheral nerve myelin antibody in patients with demyelinating neuropathy quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985;82:905-9.
23. Kornberg AJ, Pestronk A, Bieser K et al. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol 1994;35:234-7.
24. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of antiGQlb antibody in Fisher's syndrome. Neurology 1993;43:414-7.
25. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176:S92-8.
26. Yuki N, Taki T, Inagaki F et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-5.
27. Brettle RP, Gross MLP, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100.
28. Valbonesi M, Garelli S, Mosconi L, Zerbid D, Celano I. Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang 1981;41:74-8.
29. Greenwood RJ, Hughes RAC, Bowden AN et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-9.
30. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficacy of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-61.
31. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-104.
32. van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-9.
33. Plasma Exchange/Sandoglobulin Guillian-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.
34. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome. Worsening during and after treatment. Neurology 1993;43:1034-6.
35. Irani DN, Cornblath Dr Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-5.
36. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-90.
37. Taylor BV, Wijdicks EF, Poterucha JJ, Weisner RH. Chronic inflammatory demyelinating polyneuropathy complicating liver transplantation. Ann Neurol 1995;38:828-31.
38. Romanick-Schmiedl S, Miller R, Kiprov D. Extraneurologic manifestations of chronic inflammatory demyelinating peripheral neuropathy: Response to therapeutic plasmapheresis. Ann J Med 1990;89:531-4.
39. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in peripheral nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980;37:637-40.
40. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000, June;47:765-75.
41. Latov N, Gross RB, Kastelman J et al. Complement fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neurology 1981;31:1530-4.
42. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-37.
43. Pentland B, Adams GGW, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982;45:866-9.
44. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110:1617-30.
45. Mahattanakul W, Crawford TO, Griffin JW, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996;60:186-7.
46. Toyka KV, Augspach R, Wietholter H et al. Plasma exchange in chronic inflammatory polyneuropathy evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982;5:479-84.
47. Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barre syndrome by plasma exchange. Lancet 1979;2:259-60.
48. Fowler H, Vulpe M, Marks G, Egolf C, Dau PC. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide. Lancet 1979;2:1193.
49. Dyck PJ, Daube J, O'Brien P et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-5.
50. Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-66.
51. Faed JM, Day B, Pollock M, Taylor PK, Nakuda H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-5.
52. Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991;30:104-6.
53. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;46:269-12.
54. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-77.
55. Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45.
56. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995;88:493-502.
57. Huges R, Bensa BS, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
58. Kiprov DD, Nachtigall RD, Weaver RC, Jacobson A, Main EK, Garovoy MR. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. AJRI 1996;36:228-34.
59. Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apher 1999;14:149-53.
60. Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 1998;97:194-200.
61. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37:S32-42.
62. Yeung KB, Thomas PK, King RHM et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. J Neurol 1991;238:383-91.
63. Dyck PJ, Low PA, Winderbank AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-6.
64. Pestronk A, Chaudhry V, Feldman EL, Griffin JW et al. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol 1990;27:316-26.
65. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIG, randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
66. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52.
67. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18.
68. Pestronk A. Multifocal motor neuropathy, diagnosis and treatment. Neurology 1998;51:S22-4.
69. Pestronk A, Lopate G, Kornberg AJ, Elliott JL, Blume G et al. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies, improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1994;44:2027-31.
70. Azulay JP, Attarian S, Boucraut J, Pouget J. Lower motor neuron disease and signs of dysimmunity. Rev Neurol (Paris) 2000;156:372-9.
71. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998;338:1601-7.
72. Dalakas MC, Cupler EJ. Neuropathies in HIV infection. Baillieres Clin Neurol 1996;5:199-218.
73. Kiprov D, Pfaeffl W, Parry G, Lippert R, Lang W, Miller R. Antibody-mediated peripheral neuropathies associated with ARC and AIDS: successful treatment with plasmapheresis. J Clin Apher 1988;4:3-7.